Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Themes on this desk
AI policy and data centers
A White House superintelligence task force was read as supportive for AI and data-center exposure, with NBIS disclosed.
Pharma hiring freeze
Separate posts reported stalled applications and hiring freezes across large-pharma and biotech roles.
GME warrant catalyst
A large disclosed GME position was tied to a warrant-expiry catalyst, while Cohen’s ownership dilution remains the counterpoint.
Highest engagement
by score · day changeCNTB catalyst setup: China NDA milestone plus FDA Phase 3 alignment with only ~$31M cash
Author argues Connect Biopharma (CNTB) is mispriced ahead of two catalysts: partner Simcere's rademikibart NDA accepted by China's NMPA in July 2025 (potential up to $110M in milestone payments plus double-digit royalties, with China approvals typically 12-18 months), and FDA engagement on a Phase 3 path for asthma/COPD after positive Phase 2 data. CNTB had around $31M cash, so a China approval would bring non-dilutive cash and reduce financing risk; the author also flags a clean safety profile and possible additional partnering interest in COPD.
If approved, CNTB could receive milestone payments upto 110 million dollars plus future double digit royalties.
A small-cap biotech with ~$31M cash and a near-term non-dilutive milestone catalyst is a binary risk/reward setup; approval or clean FDA Phase 3 alignment would validate the asset commercially and could re-rate the stock, while financing risk remains the bear case.
Watch China NMPA approval decision on rademikibart and disclosure of milestone receipt; FDA feedback on Phase 3 asthma/COPD trial design; any equity raise or new partnership announcement.
Source →CIRC flagged as acquisition setup with Oct 7 definitive-offer deadline after rejected bid
Author notes CIRC generates over $1.2B in revenue against a $55M market cap, recently bid to acquire another company generating over $1B in revenue, had that bid rejected, and faces an Oct 7 deadline for a definitive offer.
bid to acquire another company that generates over 1b revenue, it was rejected however a deadline for a definitive offer
A tiny market cap relative to revenue plus a hard-dated M&A deadline is a classic event-driven setup; the Oct 7 date is a binary catalyst that will resolve the thesis quickly in either direction.
Watch Whether a definitive offer is announced by Oct 7 and at what price; failure to announce would likely collapse the setup.
Source →Bond allocator argues TIPS are cheap and corporate spread is near 20-year lows
A detailed Bogleheads bond plan for a 66-year-old's inherited IRA states August CPI was 3.4% y/y (core 2.4%), the Fed hiked to 3.75-4% on 9/16 (first since 2023) with markets expecting another in December, the market prices only ~2.4% inflation over 5-10 years versus 10-year TIPS paying ~2.9% above inflation, and IG corporates yield only ~0.86% over Treasuries near 20-year lows with some credit-market strain reported.
- **Corporate bonds pay little extra.** Investment-grade corporates yield ~0.86% more than Treasuries, near 20-year lows, and that gap has
This is a concrete macro read: if the market's ~2.4% inflation breakeven is too low versus 3.4% realized, TIPS are mispriced cheap and corporate credit offers poor compensation for risk, favoring Treasuries/TIPS over corporate bond ETFs.
Watch Whether December Fed hike materializes, whether CPI stays above the ~2.4% breakeven, and whether IG spreads widen from the ~0.86% level.
Source →Nova Eye's US cataract attach-rate math implies A$70m opportunity versus A$27.4m current US sales
The EYE DD argues that if just 1% of the ~4 million annual US cataract operations added iTrack, that is ~40,000 procedures and roughly A$70m of sales, more than double EYE's entire current US business (US FY26 sales A$27.4m, up 30%), with EYE at only ~4% share of 30,000-35,000 monthly US glaucoma surgeries and each extra share point worth ~A$6.5m annually.
On my maths, if just 1% of US cataract operations added iTrack, that's around 40,000 procedures and roughly A$70m of
The cataract co-procedure channel is the largest unmodeled volume driver; a small attach rate materially changes the revenue base and supports the operating-leverage thesis.
Watch Any disclosure of cataract-combined iTrack procedures or US rep productivity (currently ~A$2.35m per rep) in the September quarterly and FY27 updates.
Source →Algo study: same NQ breakout rules turn +100% on 15m into -44% on 5m purely from transaction costs
A backtest of a 20-candle NQ breakout (long only, 1 ATR stop, 2 ATR target, Apr 2021-Mar 2026, one contract) shows 5m net -44.5% (11,736 trades, PF 0.98), 15m net +100.1% (4,126 trades, PF 1.07) and 1h net +75.5% (1,212 trades, PF 1.10), while all three were profitable gross of costs; the 5m version paid $117,360 in commissions/slippage against +72.9% gross.
minute version was +72.9% gross and its execution bill came to $117,360 across those 11,736 trades, so it landed at
It quantifies how lower timeframes can destroy an edge through costs alone, a direct warning for retail algo traders scaling trade frequency and a reminder that gross backtests overstate fast-timeframe strategies.
Watch Whether the 5m variant with wider targets (spreading the same cost over fewer, bigger trades) turns net positive, and out-of-sample performance beyond the mostly-uptrending window.
Source →Most argued
by comments per upvoteNifty reversal signal hinges on close above 22611
A poster notes Nifty has not closed above the prior red candle's high for 30 trading sessions, and identifies a close above 22611 as the first clue of a reversal, with consecutive green closes above the 13ema near 23000 needed to confirm.
22611 Today Nifty broken 22611, today must close above last session high. If closes above last session high i.e.
A 30-session failure to reclaim prior highs is a persistent downtrend signature; a confirmed break would shift positioning in Indian index and F&O exposure.
Watch Whether Nifty closes above 22611 and then sustains closes above the ~23000 13ema.
Source →US to receive potash shipment from Belarus as relations thaw
A report states the US will receive a potash shipment from Belarus amid thawing relations, a shift in trade flows for a key fertilizer input.
US to receive potash shipment from Belarus as relations thaw
Potential easing of potash supply constraints and pressure on North American potash producers' pricing power; relevant to fertilizer and agricultural input equities.
Watch Whether further Belarus potash shipments to the US follow and whether North American potash prices weaken.
Source →Salton Sea geothermal could supply entire US lithium demand
An r/energy post cites a ThinkGeoEnergy article claiming that geothermal plants at the Salton Sea can supply the entirety of US lithium demand, implying a domestic, brine-based lithium source at scale.
Entire US lithium demand can be supplied by Salton Sea geothermal plants [Entire US lithium demand can be supplied by
If credible, a domestic geothermal-lithium supply would reduce US import dependence and could pressure long-run lithium pricing and the economics of conventional hard-rock and brine projects.
Watch Whether named Salton Sea operators announce commercial-scale lithium production volumes or offtakes consistent with total US demand.
Source →Utility insider describes grid planning failure and four-year interconnection queue
An r/energy poster recounts a utility employee saying they run tabletop exercises for summer blackouts, that a 340-page infrastructure deck translated into roughly twelve miles of upgraded line, that the interconnection queue is about four years deep, and that working groups focus on outage communications rather than more transformers.
actual wire that got strung. The deck was 340 pages. They added maybe twelve miles of upgraded line.
Grid capacity and interconnection delays are the binding constraint on new load (heat pumps, data centers), which supports transformer, transmission, and grid-equipment demand while capping near-term capacity additions.
Watch Whether the region's interconnection queue shortens or utilities announce transformer and transmission orders in subsequent filings.
Source →Newmont Q2 2026: gold ounces sold fell to 1.195M from 1.380M
Newmont sold 1.195 million gold ounces in Q2 2026, down from 1.380 million a year earlier, while its realized gold price rose from $3,320 to $4,414 per ounce.
Q2 2026, down from 1.380 million a year earlier.
Falling physical sales volumes mean the cash improvement is price-driven, not operational; if gold prices stall, the earnings base is weaker than headline cash flow suggests.
Watch Whether Newmont's Q3 2026 gold ounces sold recover toward the prior-year 1.380 million level, which would indicate operational recovery rather than continued volume decline.
Source →